Pacer Advisors
PCRX icon

Pacer Advisors’s Pacira BioSciences PCRX Stock Holding History

Pacer Advisors’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.4M Sell
212,814
-22,613
-10% -$535K 0.01% 665
2026
Q1 		$5.32M Buy
235,427
+46,284
+24% +$1.03M 0.01% 600
2025
Q4 		$4.9M Sell
189,143
-11,059
-6% -$263K 0.01% 716
2025
Q3 		$5.16M Sell
200,202
-186,427
-48% -$4.58M 0.01% 673
2025
Q2 		$9.24M Sell
386,629
-215,039
-36% -$5.42M 0.02% 513
2025
Q1 		$15M Sell
601,668
-2,661,169
-82% -$63.7M 0.04% 370
2024
Q4 		$61.5M Sell
3,262,837
-1,699,384
-34% -$29.8M 0.13% 175
2024
Q3 		$74.7M Buy
4,962,221
+2,799,434
+129% +$47.9M 0.16% 161
2024
Q2 		$61.9M Buy
2,162,787
+590,082
+38% +$16.8M 0.14% 178
2024
Q1 		$46M Buy
1,572,705
+531,026
+51% +$16.3M 0.11% 207
2023
Q4 		$35.1M Buy
1,041,679
+1,041,417
+397,487% +$30.5M 0.1% 220
2023
Q3 		$8.04K Sell
262
-10
-4% -$360 ﹤0.01% 2578
2023
Q2 		$10.9K Buy
+272
New +$11.2K ﹤0.01% 3370

Other funds holding PCRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Pacer Advisors's PCRX Position: Q2 2026 in Review

Pacer Advisors reduced its Pacira BioSciences (PCRX) stake by 9.6% in Q2 2026, selling an estimated $535K and leaving 212,814 shares worth $5.4M. The position accounts for 0.01% of the portfolio, ranked #665.

Pacer Advisors first reported a position in PCRX in Q2 2023 and has held it in 13 quarters since. The position peaked at $74.7M in Q3 2024. 253 funds tracked by Wall St. Rank hold PCRX as of Q2 2026.

  • Pacer Advisors held 212,814 shares of Pacira BioSciences worth $5.4M as of Q2 2026.
  • Pacer Advisors sold 22,613 Pacira BioSciences shares in Q2 2026, an estimated $535K.
  • Pacira BioSciences made up 0.01% of Pacer Advisors's portfolio in Q2 2026, its #665 holding.
  • Pacer Advisors first reported a position in Pacira BioSciences in Q2 2023 and has held it in 13 quarters since.
  • Pacer Advisors's Pacira BioSciences position peaked at $74.7M in Q3 2024.
  • 253 funds tracked by Wall St. Rank held Pacira BioSciences as of Q2 2026.

Based on Pacer Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.